Cardiac Injury After COVID-19 Vaccination: Myocarditis, Sudden Death and Cardiovascular Disease in Adults and Children

John Murphy, CEO The COVID-19 Long haul Foundation

Abstract

COVID-19 vaccination has been associated with a spectrum of cardiovascular adverse events ranging from transient chest pain and biomarker elevation to clinically overt myocarditis, myopericarditis, pericarditis, ventricular dysfunction, arrhythmia and, in exceptionally rare circumstances, fatal cardiac injury. The association is strongest and most reproducible for myocarditis and pericarditis following mRNA vaccination, particularly in adolescent and young adult males, usually within several days after a second dose. The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and international pharmacovigilance systems now recognize this association. [1–3]

The pathological substrate of post-vaccination myocardial disease, however, is considerably more heterogeneous than the clinical label “myocarditis” implies. Endomyocardial biopsy and autopsy studies have demonstrated lymphocytic myocarditis, lymphohistiocytic inflammatory cardiomyopathy, eosinophilic inflammation, giant-cell myocarditis, myocardial edema, focal cardiomyocyte necrosis, contraction-band necrosis, interstitial inflammation and, in some cases, a pattern resembling catecholamine-mediated toxic or stress cardiomyopathy. In several series, CD4-positive T lymphocytes and macrophages predominate. Some investigations have detected SARS-CoV-2 spike protein in myocardial tissue without demonstrable viral infection, whereas others have found no viral genomes and no evidence of active SARS-CoV-2 infection. [4–10]

Autopsy evidence is particularly important because myocardial inflammation can be focal and may be missed by limited sampling. A German autopsy series identified acute lymphocytic myocarditis or myopericarditis in four of 25 unexpected deaths occurring within 20 days of vaccination, with predominantly CD4-positive T-cell infiltrates and associated myocyte injury. [8] A separate report of two adolescent boys found myocardial injury characterized more by contraction-band injury resembling catecholamine-mediated toxic cardiomyopathy than by conventional myocarditis. [9] These apparently disparate observations underscore the need to distinguish several potentially overlapping pathological mechanisms rather than assume a single lesion.

The pediatric experience deserves particular attention. Vaccine-associated myocarditis occurs predominantly in adolescent males, most often after the second mRNA dose. Most clinically recognized pediatric cases have been mild, with rapid improvement in ventricular function and symptoms. Nevertheless, cardiac magnetic resonance imaging (CMR) frequently demonstrates myocardial injury, and late gadolinium enhancement (LGE), a marker of myocardial fibrosis or persistent injury, may remain after symptoms and ventricular function normalize. In one pediatric follow-up study, LGE persisted in 80% of children at approximately three months despite clinical improvement. [11] A larger systematic review similarly found persistent LGE in approximately three-quarters of patients at intermediate follow-up. [12] The long-term prognostic significance of small residual LGE remains uncertain.

The appropriate scientific conclusion is therefore neither that COVID-19 vaccines produce widespread irreversible cardiac injury nor that post-vaccination cardiac disease can be dismissed as coincidental. The evidence supports a genuine, uncommon vaccine-associated myocarditis/pericarditis syndrome, while the evidence for other cardiovascular conditions is considerably more heterogeneous. Establishing causality for an individual patient requires integration of clinical chronology, electrocardiography, troponin, echocardiography, CMR, coronary anatomy, endomyocardial biopsy when indicated, histopathology, immunohistochemistry, molecular testing, microbiology, serology and, in fatal cases, comprehensive autopsy.

1. Introduction

The cardiovascular safety profile of COVID-19 vaccines has evolved substantially since the introduction of mRNA vaccination. Initial randomized clinical trials were not large enough to detect very rare cardiovascular events, particularly events concentrated in narrow age-sex strata. Subsequent population surveillance identified an excess of myocarditis and pericarditis following mRNA vaccination, most conspicuously among adolescent and young adult males after the second dose.

The signal is now sufficiently established that CDC states that evidence from multiple U.S. and international vaccine-safety monitoring systems supports a causal association between mRNA COVID-19 vaccines and myocarditis/pericarditis. [1] The FDA subsequently required updated labeling for the Pfizer-BioNTech and Moderna mRNA vaccines to include additional myocarditis/pericarditis risk information and cardiac-MRI findings. [2]

This recognition does not resolve the more difficult pathological questions.

What precisely happens to the myocardium?

Is the lesion conventional lymphocytic myocarditis?

Is it an immune-mediated cardiomyopathy?

Is there endothelial injury?

Does complement activation contribute?

Does spike-protein expression occur within cardiomyocytes?

Can microvascular thrombosis produce focal myocardial necrosis?

Can catecholamine-mediated injury contribute?

Why are young males disproportionately affected?

Why does most clinically apparent disease resolve while CMR abnormalities may persist?

And, most importantly, which myocardial abnormalities are reversible and which represent permanent structural injury?

These questions require a pathology-centered framework.

2. The Cardiovascular Phenotypes Reported After Vaccination

The reported cardiovascular spectrum includes:

myocarditis;
myopericarditis;
pericarditis;
acute myocardial injury with elevated troponin;
left-ventricular systolic dysfunction;
inflammatory cardiomyopathy;
fulminant myocarditis;
giant-cell myocarditis;
eosinophilic myocarditis;
stress/Takotsubo-like cardiomyopathy;
arrhythmias;
sudden cardiac arrest;
sudden cardiac death;
myocardial infarction;
MINOCA;
coronary thrombosis;
microvascular thrombosis;
endothelial injury;
pulmonary embolism with secondary right-heart strain;
VITT-associated cardiac injury;
hypertension;
tachycardia;
heart failure;
aortitis;
aortic dissection;
cardiogenic shock; and
multisystem inflammatory syndromes involving the cardiovascular system.

A large review of cardiovascular sequelae reported myocarditis and thrombosis as the most frequently described vaccine-associated cardiovascular complications, while also identifying pericarditis, acute coronary syndromes, stress cardiomyopathy, hypertension, tachycardia, MINOCA, cardiac arrest, VITT, myocardial infarction, venous thrombosis and pulmonary embolism. [13]

The evidence, however, is not equivalent across these conditions.

Myocarditis/pericarditis: strong epidemiologic and mechanistic evidence.

Stress cardiomyopathy: biologically plausible, with case reports and pathological parallels, but substantially weaker epidemiologic evidence.

Myocardial infarction: reported, but difficult to distinguish from background incidence and conventional cardiovascular disease.

Arrhythmia: biologically plausible and documented in individual cases, but causation is heterogeneous.

Thrombosis/VITT: well-established principally with certain adenoviral-vector vaccines rather than as a generalized mRNA-vaccine phenomenon.

Aortic dissection/aortitis: very rare case-report-level evidence.

This distinction is essential for a scientifically defensible pathology paper.

3. Myocarditis: The Principal Cardiac Adverse Event

Myocarditis is inflammation of cardiac muscle. Histologically, conventional myocarditis consists of inflammatory infiltrates associated with cardiomyocyte injury or necrosis.

The Dallas classification historically emphasized inflammatory infiltration and associated myocyte injury, although contemporary diagnosis increasingly integrates CMR, immunohistochemistry and molecular testing.

Post-vaccination myocarditis generally has a distinctive clinical phenotype:

young age;
male predominance;
onset within several days;
frequent occurrence after dose 2;
chest pain;
elevated troponin;
ST-segment abnormalities;
preserved or mildly depressed ventricular function in most patients;
CMR evidence of edema and non-ischaemic myocardial injury.

CDC states that cases occur most frequently in adolescent and young adult males within seven days after the second mRNA dose, although cases also occur in females, other age groups and after other doses. [1]

4. Pediatric and Adolescent Myocarditis

The pediatric phenotype is one of the most important findings in the vaccine-safety literature.

A multicenter U.S. study of 63 patients younger than 21 years with vaccine-associated myocarditis found a mean age of approximately 15.6 years and a 92% male predominance. Nearly all had received an mRNA vaccine after the second dose. Four patients experienced significant dysrhythmia, while 14% had mild left-ventricular dysfunction that resolved by discharge. CMR demonstrated findings meeting Lake Louise myocarditis criteria in approximately 88%. [14]

This phenotype is markedly different from the typical clinical profile of conventional severe myocarditis in adults.

In most pediatric cases:

ventricular function recovers rapidly;
symptoms resolve;
hospitalization is brief;
serious heart failure is uncommon;
transplantation is exceedingly uncommon;
death is extraordinarily rare.

However, “clinically recovered” should not be equated automatically with “histologically normal.”

5. Persistent Myocardial Abnormality in Children

The most important unresolved pediatric question concerns residual myocardial injury.

A Boston Children’s Hospital study followed adolescents with vaccine-associated myocarditis using CMR. At approximately 92 days after hospitalization, LGE remained present in 80% of patients, although it had decreased in extent in every patient. [11]

A subsequent systematic review and meta-analysis involving 126 patients found persistent LGE in approximately 76% at intermediate follow-up. Symptoms had resolved in essentially all patients, while LVEF generally improved. [12]

Another pediatric registry found that at three months approximately 29% still reported symptoms and 47% retained diagnostic abnormalities; among patients evaluated at nine months, 43% still had diagnostic abnormalities, predominantly residual LGE. Importantly, no severe heart failure, transplantation or death occurred in that cohort. [15]

These findings create an important pathological distinction:

Clinical recovery ≠ complete anatomical recovery.

LGE can represent residual fibrosis, scar, extracellular matrix expansion or residual injury. Whether small areas of persistent LGE after vaccine-associated myocarditis increase future risk of ventricular arrhythmia or dilated cardiomyopathy remains unknown.

Long-term surveillance therefore deserves considerably more attention than simply documenting resolution of chest pain and normalization of troponin.

6. Histopathology of Vaccine-Associated Myocarditis

The pathological spectrum is broader than classical lymphocytic myocarditis.

Reported lesions include:

patchy lymphocytic myocarditis;
CD4-predominant inflammation;
CD8-positive cytotoxic lymphocytes;
macrophage accumulation;
eosinophilic inflammation;
myocyte necrosis;
interstitial edema;
perivascular inflammation;
giant-cell myocarditis;
inflammatory cardiomyopathy;
contraction-band necrosis;
focal single-cell necrosis;
myocardial hemorrhage;
fibrosis;
pericardial inflammation;
epicardial inflammation.

A biopsy series of 15 patients with clinically suspected post-vaccination myocarditis found myocardial inflammation in 14 patients. The histopathological diagnoses included acute myocarditis, giant-cell myocarditis and inflammatory cardiomyopathy. Infectious causes were excluded in the study. Spike protein was detected sparsely in cardiomyocytes in nine patients, while CD4/CD8 patterns suggested an immune-mediated process. The investigators explicitly cautioned that definitive causation could not be demonstrated. [6]

This is a significant finding because it moves the discussion beyond the question of whether inflammation exists to the more important question of what kind of inflammation exists.

7. Endomyocardial Biopsy

Endomyocardial biopsy is not required for every clinically mild case of suspected myocarditis.

Nevertheless, biopsy becomes particularly informative when:

ventricular function is substantially reduced;
cardiogenic shock develops;
arrhythmias are severe;
fulminant myocarditis is suspected;
giant-cell myocarditis is a possibility;
eosinophilic myocarditis is suspected;
the diagnosis is uncertain;
CMR findings are atypical;
treatment decisions depend upon histological diagnosis.

A 24-patient biopsy series reported acute lymphocytic myocarditis in 20.8%, chronic lymphocytic myocarditis in 25%, healed myocarditis in 25%, cardiac sarcoidosis in 4.2% and other cardiac injuries in the remainder. [7]

Another series of 15 patients found two cases meeting Dallas criteria for acute myocarditis, two cases of severe giant-cell myocarditis and ten cases of inflammatory cardiomyopathy. [6]

These findings demonstrate why the term “vaccine myocarditis” should not substitute for a morphological diagnosis.

8. Giant-Cell Myocarditis

Giant-cell myocarditis is a rare but potentially devastating inflammatory myocardial disease.

The pathological findings include:

extensive inflammatory infiltration;
multinucleated giant cells;
cardiomyocyte destruction;
necrosis;
macrophage accumulation;
frequently severe ventricular dysfunction.

Its identification is clinically crucial because the prognosis and treatment differ substantially from uncomplicated lymphocytic myocarditis.

The existence of giant-cell myocarditis in post-vaccination biopsy series does not establish that vaccination caused every such case. Nevertheless, it demonstrates that severe immune-mediated myocardial inflammation can occur in temporal association with vaccination and should not be excluded merely because the patient recently received a vaccine. [6]

9. Eosinophilic Myocarditis

Eosinophilic myocarditis represents another important differential diagnosis.

Potential causes include:

medications;
hypersensitivity reactions;
parasitic infection;
systemic eosinophilic disorders;
autoimmune disease;
and potentially immune reactions temporally associated with vaccination.

Histologically, eosinophils infiltrate the myocardium and may produce cardiomyocyte injury.

A large Japanese histopathological investigation of myocarditis following mRNA vaccination found several patterns, including lymphocytic, eosinophilic and mixed lymphocytic/eosinophilic inflammation. Importantly, cardiomyocyte injury was strongly associated with clinical severity. Among patients with demonstrable cardiomyocyte injury, 71.4% developed fulminant myocarditis and most required mechanical circulatory support. [10]

This observation has major pathological importance:

Inflammation alone is not necessarily equivalent to severe myocardial injury. Cardiomyocyte destruction appears to be a critical determinant of clinical severity.

10. CD4 and CD8 T-Cell Biology

Several pathological investigations have demonstrated prominent T-cell infiltration.

The German autopsy series of unexpected deaths after vaccination identified patchy interstitial T-lymphocytic infiltrates, predominantly CD4-positive, with mild cardiomyocyte damage. [8]

Other biopsy studies have demonstrated:

CD3-positive lymphocytes;
CD4-positive helper T cells;
CD8-positive cytotoxic T cells;
activated T cells;
macrophages;
perforin-positive cells;
HLA-DR-positive activated immune cells.

This pattern raises the possibility of an antigen-driven or autoimmune myocardial reaction.

It does not, however, establish whether the immune response is directed against:

vaccine-derived antigen;
myocardial proteins;
modified self-antigens;
molecularly mimetic epitopes;
damaged-cell antigens;
lipid-nanoparticle-associated inflammatory signals;
or a combination of these.

11. Spike Protein in the Myocardium

One of the most controversial molecular findings is detection of SARS-CoV-2 spike protein within cardiac tissue.

In one endomyocardial biopsy series, spike protein was detected sparsely within cardiomyocytes in nine patients. [6]

The interpretation requires caution.

Detection of antigen does not establish:

productive viral infection;
direct cytotoxicity;
persistent replication;
vaccine causation;
or the mechanism of myocardial injury.

A critical experimental question is whether the detected protein is:

intact vaccine-derived spike;
translated antigen;
antigen taken up by antigen-presenting cells;
cross-reactive endogenous protein;
or an artifact of immunohistochemical cross-reactivity.

Future pathology studies should therefore employ orthogonal confirmation using:

multiple spike antibodies;
nucleocapsid staining;
RNA in-situ hybridization;
quantitative PCR;
digital PCR;
spatial transcriptomics;
mass spectrometry;
and, where feasible, proteomic sequencing.

12. SARS-CoV-2 Infection Must Always Be Excluded

The major confounder in studies of vaccine-associated cardiac disease is SARS-CoV-2 infection.

COVID-19 itself can produce:

myocarditis;
endothelial injury;
coronary thrombosis;
microvascular thrombosis;
myocardial infarction;
stress cardiomyopathy;
arrhythmia;
heart failure;
pulmonary embolism;
right-ventricular failure;
and multisystem inflammatory disease.

Therefore, a patient who develops myocarditis after vaccination cannot automatically be categorized as having vaccine-induced myocarditis without evaluating infection.

Recommended investigations include:

SARS-CoV-2 PCR;
antigen testing;
anti-nucleocapsid antibodies when appropriate;
exposure history;
recent infection history;
viral sequencing where available;
tissue SARS-CoV-2 RNA in autopsy cases.

This distinction is particularly important because infection itself may produce cardiac microvascular thrombosis and myocardial injury without conventional lymphocytic myocarditis. [16]

13. Myocardial Edema

Acute myocardial edema is a central pathological component of myocarditis.

CMR identifies edema through:

T2-weighted imaging;
T2 mapping;
increased native T1;
extracellular-volume expansion.

Histologically, edema appears as expansion of the interstitial compartment separating cardiomyocytes.

Edema can be reversible.

This distinction is critical because the acute CMR appearance may be alarming while subsequent imaging demonstrates normalization of myocardial water content and ventricular function.

In a follow-up study of patients with vaccine-associated myocarditis, myocardial edema resolved and LVEF normalized in all patients who had paired studies, although minimal LGE persisted in approximately 48%. [17]

14. Cardiomyocyte Necrosis

Cardiomyocyte necrosis is more consequential than edema alone.

Histological patterns include:

hypereosinophilic cytoplasm;
loss of cross-striation;
nuclear pyknosis;
karyorrhexis;
fragmentation;
contraction-band necrosis;
coagulative necrosis;
inflammatory-cell association.

Necrosis may heal through:

complete cellular recovery in reversible injury;
phagocytic removal;
replacement by extracellular matrix;
focal fibrosis.

The final pathway determines whether a patient has no residual abnormality or persistent scar.

15. Contraction-Band Necrosis and Catecholamine Injury

Contraction-band necrosis deserves special attention.

It is characterized histologically by intensely eosinophilic transverse bands produced by hypercontraction of sarcomeres.

It is classically associated with:

catecholamine excess;
stress cardiomyopathy;
reperfusion injury;
neurological catastrophes;
severe physiological stress.

In two adolescent boys who died shortly after a second Pfizer dose, cardiac histology demonstrated a pattern resembling catecholamine-induced injury rather than conventional myocarditis. [9]

The authors interpreted the lesions as resembling toxic/stress cardiomyopathy.

This observation is important because it suggests that not every fatal post-vaccination myocardial injury necessarily represents conventional inflammatory myocarditis.

A severe immune response could theoretically interact with:

sympathetic activation;
catecholamine release;
inflammatory cytokines;
endothelial dysfunction;
myocardial calcium handling;
mitochondrial injury.

The resulting phenotype might therefore combine inflammation and stress-mediated cardiomyocyte injury.

16. Fatal Myocarditis

Fatal vaccine-associated myocarditis is extraordinarily uncommon, but pathological documentation exists.

A Korean autopsy report described a 22-year-old man who developed chest pain five days after his first BNT162b2 dose and died seven hours later. Autopsy showed isolated atrial myocarditis with neutrophil and histiocyte predominance, C4d-positive single-cell cardiomyocyte necrosis and extensive contraction-band necrosis. No cardiac microthrombosis or infection was identified. [18]

Another fatal case involved a 61-year-old woman who developed fever three days after vaccination, shock the following day and died ten days later. Autopsy showed severe myocarditis with extensive myocytolysis, T-lymphocyte and macrophage infiltration, neutrophilic nuclear debris and hemophagocytosis. Broad molecular testing failed to identify cardiotropic viruses. [19]

These cases cannot establish population-level mortality rates, but they demonstrate that severe and occasionally fatal myocardial injury can occur.

17. Autopsy Series

The most extensive dedicated autopsy investigation identified 25 unexpected deaths occurring within 20 days after vaccination. Four patients who had received mRNA vaccines demonstrated acute myocarditis or myopericarditis without another major disease process sufficient to explain death. Histology showed patchy interstitial T-cell infiltration, predominantly CD4-positive, with associated myocyte damage. The authors interpreted the mechanism of death as acute arrhythmogenic cardiac failure. [8]

A separate systematic review identified 28 reported autopsy cases in which vaccine-associated myocarditis was considered a possible cause of death. The authors concluded that the cases were likely causally related after independent clinical-pathological review. [20]

That conclusion should be interpreted cautiously because autopsy case series are inherently subject to:

selection bias;
publication bias;
incomplete denominator data;
referral bias;
differential autopsy practices;
retrospective adjudication;
and uncertain background mortality.

Nevertheless, the pathological convergence across several reports is noteworthy.

18. Arrhythmia and Sudden Cardiac Death

The myocardium is an electrically active organ. Small regions of inflammation or fibrosis can potentially disturb:

conduction;
repolarization;
automaticity;
re-entry;
ventricular excitability.

Reported clinical abnormalities include:

sinus tachycardia;
premature ventricular contractions;
atrial arrhythmias;
ventricular tachycardia;
conduction abnormalities;
ST-segment abnormalities;
sudden cardiac arrest.

A Japanese autopsy report described a previously healthy 40-year-old man who developed tachycardia and loss of consciousness two days after vaccination and subsequently died. Histological examination demonstrated scattered inflammatory foci and cardiomyocyte necrosis in both ventricles. [21]

The key pathological problem is that fatal arrhythmia may occur with surprisingly little structural disease.

Consequently:

A negative or minimally abnormal gross autopsy does not exclude an arrhythmogenic cardiac death.

Forensic evaluation should therefore include:

extensive myocardial sampling;
conduction-system examination where appropriate;
toxicology;
coronary evaluation;
molecular testing for inherited arrhythmia syndromes where indicated;
histology;
immunohistochemistry;
clinical ECG analysis.

19. Pericarditis

Pericarditis may occur independently or together with myocarditis.

Pathological findings can include:

serous effusion;
fibrin deposition;
mesothelial reaction;
lymphocytes;
macrophages;
neutrophils;
vascular congestion;
fibrosis in chronic cases.

A reported autopsy following mRNA vaccination described aortic dissection, hemopericardium and pericardial inflammation consisting predominantly of macrophages and lymphocytes, together with inflammation extending into the aortic adventitia. [22]

This remains a case report and cannot establish that vaccination caused the aortic dissection.

It does, however, illustrate why post-vaccination cardiovascular autopsies should not restrict sampling to the myocardium.

20. Aortitis and Aortic Dissection

Aortic inflammation has occasionally been reported following vaccination.

Potential pathological findings include:

adventitial inflammatory infiltrates;
lymphocytes;
macrophages;
medial degeneration;
necrosis;
hemorrhage;
dissection.

The biological plausibility is uncertain and the evidence is currently much weaker than for myocarditis.

In particular, older patients frequently possess pre-existing:

atherosclerosis;
medial degeneration;
hypertension;
aneurysmal disease;
connective-tissue abnormalities.

Therefore, temporal association alone is insufficient to attribute aortic dissection to vaccination.

21. Myocardial Infarction

Myocardial infarction following vaccination has been reported.

Possible mechanisms include:

Conventional plaque rupture

Vaccination-related systemic inflammation could theoretically destabilize an existing atherosclerotic plaque.

Coronary thrombosis

A prothrombotic state could produce coronary occlusion.

Microvascular thrombosis

Small-vessel thrombosis could cause scattered myocardial necrosis without epicardial coronary occlusion.

Vasospasm

Transient coronary vasoconstriction can produce ischemia without persistent coronary obstruction.

Demand ischemia

Fever, tachycardia, hypoxia or systemic inflammation may increase myocardial oxygen demand.

Myocarditis mimicking infarction

Inflammatory myocardial injury can produce:

chest pain;
ST elevation;
troponin elevation;

and therefore mimic acute coronary syndrome.

CMR and coronary angiography are particularly valuable in distinguishing these mechanisms.

22. MINOCA

Myocardial infarction with non-obstructive coronary arteries (MINOCA) presents a diagnostic challenge.

Potential pathological mechanisms include:

plaque erosion;
transient thrombosis;
coronary spasm;
spontaneous coronary artery reperfusion;
microvascular thrombosis;
myocarditis;
Takotsubo syndrome.

Accordingly, a patient with post-vaccination chest pain and elevated troponin should not automatically be labeled as having either “myocarditis” or “myocardial infarction.”

CMR is particularly important because it can distinguish:

ischemic LGE;
non-ischemic LGE;
myocardial edema;
Takotsubo patterns;
and focal myocarditis.

23. Microvascular Thrombosis

Microvascular thrombosis is an important potential mechanism of myocardial injury.

COVID-19 infection itself produces extensive myocardial microthrombosis. Autopsy studies have shown fibrin-rich and complement-associated microthrombi in myocardial vessels. [23]

A separate post-vaccination autopsy report described multiple small thrombi in the heart, brain, liver, kidney and adrenal glands. The thrombi were CD61/CD42b positive and had a distribution resembling thrombotic microangiopathy. [24]

This is intriguing but must be interpreted as a single-case observation.

The appropriate research question is not simply whether microthrombi exist, but whether post-vaccination myocardial microthrombosis occurs at a rate above background and through a reproducible biological mechanism.

24. Platelet Activation and Complement

The immunopathology of cardiovascular injury potentially includes:

platelet activation;
complement activation;
endothelial activation;
neutrophil extracellular traps;
tissue-factor expression;
coagulation activation;
endothelial apoptosis;
microvascular obstruction.

Complement components such as:

C3;
C4d;
C5b-9;

should therefore be evaluated in appropriate pathological specimens.

C4d deposition in cardiomyocytes has been described in an autopsy case of fatal post-vaccination myocarditis. [18]

Whether complement activation is a primary mechanism or a secondary consequence of tissue injury remains unresolved.

25. VITT and Thrombotic Cardiovascular Injury

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a distinct syndrome most strongly associated with adenoviral-vector vaccines.

Its pathological basis involves antibodies against platelet factor 4 (PF4), producing profound platelet activation and thrombosis.

Potential cardiovascular consequences include:

pulmonary embolism;
coronary thrombosis;
myocardial infarction;
right-ventricular strain;
shock.

VITT must therefore be distinguished from mRNA-vaccine-associated myocarditis.

The mechanisms are fundamentally different:

Myocarditis: predominantly inflammatory myocardial injury.

VITT: antibody-mediated platelet activation and thrombosis.

Combining both under a generic category of “vaccine cardiac injury” obscures rather than clarifies pathogenesis.

26. Stress Cardiomyopathy/Takotsubo Syndrome

Takotsubo syndrome is characterized clinically by transient ventricular dysfunction, commonly involving apical ballooning.

Histologically, reported lesions include:

contraction-band necrosis;
myocardial edema;
focal cardiomyocyte injury;
macrophage accumulation.

The pathological pattern is consistent with excessive catecholamine stimulation.

Because two adolescent post-vaccination autopsies demonstrated contraction-band injury resembling catecholamine-mediated cardiomyopathy, this mechanism deserves additional investigation. [9]

Potential mediators include:

systemic inflammatory signaling;
cytokines;
sympathetic activation;
catecholamines;
endothelial dysfunction;
calcium overload;
oxidative stress.

At present, however, the evidence for a causal vaccine-Takotsubo relationship is substantially weaker than the evidence for myocarditis.

27. Endothelial Injury

The cardiovascular endothelium is potentially relevant because endothelial dysfunction can produce:

vasoconstriction;
platelet adhesion;
thrombosis;
altered vascular permeability;
inflammation;
microvascular ischemia.

Potential pathological markers include:

CD31;
von Willebrand factor;
ICAM-1;
VCAM-1;
E-selectin;
tissue factor;
complement deposition.

Future autopsy investigations should evaluate the coronary microcirculation systematically rather than limiting analysis to large coronary arteries.

28. Mitochondrial Injury

Cardiomyocytes possess an extraordinarily high mitochondrial density.

Potential consequences of inflammatory or oxidative injury include:

mitochondrial swelling;
cristae disruption;
impaired oxidative phosphorylation;
ATP depletion;
calcium dysregulation;
increased reactive oxygen species;
permeability transition;
cardiomyocyte apoptosis or necrosis.

Electron microscopy should therefore be considered in severe unexplained cases.

A particularly important research question is whether mitochondrial abnormalities persist after the acute inflammatory phase.

29. Molecular Pathology

A modern investigation of post-vaccination cardiac injury should include molecular pathology.

Viral testing

SARS-CoV-2 PCR;
broad respiratory-virus PCR;
enterovirus;
adenovirus;
parvovirus B19;
HHV-6;
EBV;
CMV;
other cardiotropic viruses.

Vaccine-associated antigen testing

spike protein;
nucleocapsid protein;
vaccine-specific RNA where technically feasible.

Immune profiling

CD3;
CD4;
CD8;
CD20;
CD68;
CD163;
perforin;
HLA-DR.

Complement

C3;
C4d;
C5b-9.

Endothelial markers

CD31;
vWF;
ICAM-1;
VCAM-1.

Thrombosis

CD61;
CD42b;
fibrin;
platelet aggregates.

30. Genomic Investigation

Patients with unusually severe myocarditis should be considered for genomic investigation.

Potential predispositions include genes involved in:

immune regulation;
cardiomyocyte structural proteins;
ion channels;
mitochondrial function;
inflammatory signaling.

Important differential diagnoses include:

familial dilated cardiomyopathy;
arrhythmogenic cardiomyopathy;
hypertrophic cardiomyopathy;
long-QT syndromes;
Brugada syndrome;
catecholaminergic polymorphic ventricular tachycardia.

Genetic susceptibility could help explain why a rare adverse event occurs preferentially in a small subset of vaccinated individuals.

31. Transcriptomics

Single-cell RNA sequencing could distinguish:

activated CD4 T cells;
CD8 cytotoxic cells;
macrophage subsets;
endothelial cells;
fibroblasts;
injured cardiomyocytes.

Spatial transcriptomics could determine whether immune activation is:

diffuse;
perivascular;
localized to cardiomyocyte clusters;
associated with microvascular thrombosis;
or concentrated around areas of myocyte necrosis.

This would be substantially more informative than conventional H&E microscopy alone.

32. Electron Microscopy

Transmission electron microscopy should be considered in severe or fatal cases.

Potential targets include:

Cardiomyocytes

mitochondrial swelling;
disrupted cristae;
sarcomere injury;
intracellular vacuolization.

Endothelium

swelling;
loss of fenestration;
endothelial detachment;
basement-membrane abnormalities.

Capillaries

platelet aggregates;
fibrin;
endothelial injury.

Interstitium

edema;
collagen deposition;
inflammatory-cell interactions.

Electron microscopy could help discriminate direct cellular injury from predominantly immune-mediated disease.

33. Autopsy Protocol for Suspected Vaccine-Associated Cardiac Death

A complete cardiovascular autopsy should include:

Gross examination

heart weight;
chamber dimensions;
wall thickness;
coronary arteries;
myocardium;
valves;
pericardium;
aorta;
pulmonary arteries.

Coronary arteries

Serial sectioning should evaluate for:

plaque rupture;
plaque erosion;
thrombosis;
dissection;
vasospasm-related changes;
anomalous anatomy.

Myocardial sampling

At minimum:

interventricular septum;
right ventricle;
left ventricle;
apex;
anterior wall;
lateral wall;
posterior wall;
right atrium;
left atrium where indicated.

Sampling should be substantially more extensive when myocarditis is suspected because inflammation can be focal.

Histology

H&E;
Masson trichrome;
elastic stains where indicated;
Congo red where indicated;
Oil Red O on frozen tissue where appropriate.

Immunohistochemistry

CD3;
CD4;
CD8;
CD20;
CD68;
CD163;
C4d;
C5b-9;
fibrin;
CD61;
viral antigens;
spike;
nucleocapsid.

Molecular studies

SARS-CoV-2 PCR;
broad viral PCR;
RNA in-situ hybridization;
vaccine-antigen studies where validated.

Toxicology

stimulants;
opioids;
medications;
catecholamine-associated substances;
other potential cardiotoxins.

Serology

SARS-CoV-2 antibodies;
anti-nucleocapsid antibodies;
PF4 antibodies when VITT is suspected.

34. Pathological Differential Diagnosis

Finding	Possible interpretation	Important alternatives
Lymphocytic myocarditis	Immune-mediated myocarditis	Viral myocarditis
CD4 predominance	Immune activation	Nonspecific inflammation
Eosinophils	Hypersensitivity myocarditis	Parasites, systemic eosinophilia
Giant cells	Giant-cell myocarditis	Sarcoidosis
Contraction bands	Catecholamine injury	Ischaemia, resuscitation
Focal necrosis	Myocarditis or ischemia	CPR-related injury
C4d/C5b-9	Complement activation	Secondary tissue injury
Microthrombi	Endothelial/platelet process	DIC, infection, VITT
LGE on CMR	Fibrosis/injury	Prior myocarditis
Elevated troponin	Cardiomyocyte injury	MI, PE, renal disease, sepsis
Pericardial inflammation	Pericarditis	Infection, autoimmune disease
Coronary thrombosis	Acute MI	Atherosclerotic plaque rupture
Multivessel microthrombosis	Systemic thrombosis	VITT, DIC
Contraction-band necrosis + ballooning	Stress cardiomyopathy	Ischemia
Aortic inflammation	Aortitis	Degenerative disease

35. Children: Vaccine Myocarditis Versus MIS-C

This distinction is critical.

MIS-C is a post-infectious inflammatory syndrome associated with SARS-CoV-2 infection.

It can produce:

myocardial dysfunction;
coronary abnormalities;
shock;
pericardial effusion;
elevated inflammatory markers;
elevated troponin;
ventricular dysfunction.

Pediatric COVID-19 autopsy studies have documented:

interstitial myocardial edema;
band necrosis;
fibrin microthrombi;
interstitial inflammation;
perivascular inflammation;
pancarditis. [25]

These findings overlap substantially with potential vaccine-associated cardiac injury.

Consequently, pediatric pathology requires rigorous differentiation between:

SARS-CoV-2 infection

and

vaccine-associated immune activation.

Nucleocapsid testing is particularly useful because the vaccine encodes spike rather than nucleocapsid.

36. Recovery: What Happens to the Heart?

The prognosis of clinically recognized vaccine-associated myocarditis is generally favorable.

In pediatric cohorts:

ventricular dysfunction generally resolves;
symptoms usually disappear;
severe heart failure is uncommon;
death is extraordinarily uncommon.

However, CMR frequently demonstrates residual LGE.

This produces three levels of recovery:

Level I — Clinical recovery

No chest pain, dyspnea or exercise intolerance.

Level II — Functional recovery

Normal:

LVEF;
ventricular volumes;
wall motion.

Level III — Structural recovery

No:

edema;
LGE;
fibrosis;
residual myocardial abnormality.

Many patients reach Levels I and II without necessarily reaching Level III.

This distinction should be incorporated into future vaccine-safety studies.

37. Why Persistent LGE Matters

LGE generally reflects abnormal extracellular space caused by:

fibrosis;
necrosis;
inflammation;
extracellular matrix expansion.

Persistent LGE after myocarditis is potentially relevant because myocardial scar can provide a substrate for:

ventricular arrhythmias;
re-entry;
future ventricular dysfunction.

It does not follow that every adolescent with residual LGE will develop a cardiac complication.

The long-term risk remains one of the most important unresolved questions.

Longitudinal CMR studies extending five to ten years would be substantially more informative than the currently available three-to-twelve-month observations.

38. The Male-Adolescent Predilection

The striking concentration of cases among young males remains unexplained.

Potential hypotheses include:

sex hormones;
androgen effects on immune signaling;
testosterone-dependent immune responses;
differences in innate immunity;
differences in myocardial ACE2 biology;
differences in lipid-nanoparticle distribution;
differences in vaccine pharmacokinetics;
genetic factors;
prior antigen exposure.

The epidemiological pattern is real even though the biological explanation remains uncertain.

CDC surveillance has repeatedly identified the highest rates among young males, particularly after dose 2. [1,3]

39. Dose and Product Effects

The risk is not uniform.

The highest observed rates historically occurred after:

the second dose;
mRNA vaccination;
particularly in adolescent and young adult males.

Dose spacing and product formulation appear to influence risk.

CDC data have shown substantial variation by age, sex, vaccine and dose. For example, surveillance following monovalent Pfizer booster doses reported substantially higher myocarditis/pericarditis rates in adolescent males than females, while the absolute rates in older age groups were much lower. [3]

Therefore, analyses should never report a single population-wide myocarditis rate without stratification by:

age;
sex;
product;
dose;
interval;
formulation;
prior infection.

40. Other Cardiovascular Conditions

The evidence for non-myocarditis cardiovascular conditions is considerably less secure.

Hypertension

Transient increases in blood pressure have been reported.

Potential mechanisms include:

sympathetic activation;
stress;
pain;
inflammatory signaling;
endothelial dysfunction.

Chronic vaccine-induced hypertension has not been established as a major cardiovascular adverse effect.

Tachycardia

Transient tachycardia is common after systemic immune activation.

Persistent tachycardia requires evaluation for:

myocarditis;
dysautonomia;
anemia;
infection;
dehydration;
thyroid disease;
arrhythmia.

Heart failure

Heart failure following vaccination is most plausibly secondary to:

myocarditis;
stress cardiomyopathy;
ischemia;
arrhythmia;
thrombotic disease.

Pulmonary embolism

Pulmonary embolism may secondarily cause:

right-ventricular dilation;
right-heart strain;
elevated troponin;
pulmonary hypertension;
shock.

It should not automatically be interpreted as myocarditis.

41. Pathological Criteria for Causal Attribution

A practical pathology classification should separate association from causation.

Grade 0 — No evidence

No pathological abnormality attributable to the cardiovascular system.

Grade 1 — Temporal association only

Cardiac event occurred after vaccination but pathology is nonspecific.

Grade 2 — Compatible pathology

Pathology is biologically compatible with a vaccine-associated process but alternatives remain.

Grade 3 — Strong pathological association

Characteristic inflammatory or vascular lesion plus:

appropriate chronology;
absence of infection;
absence of competing explanation;
supportive molecular findings.

Grade 4 — Highly persuasive causation

Requires convergence of:

temporal relationship;
characteristic pathology;
molecular evidence;
exclusion of infection;
exclusion of alternative causes;
biological plausibility;
consistency with epidemiology;
and ideally reproducibility.

This framework is preferable to simply labeling every cardiac death following vaccination as “vaccine-induced.”

42. Recommended Clinical Evaluation

For a patient presenting after vaccination with:

chest pain;
dyspnea;
palpitations;
syncope;
unexplained tachycardia;
exercise intolerance;

initial evaluation should include:

ECG;
troponin;
inflammatory markers;
echocardiography when indicated;
SARS-CoV-2 testing;
other viral testing where clinically appropriate;
CMR when myocarditis is suspected;
cardiology consultation.

CDC specifically recommends ECG, troponin and inflammatory markers as part of the initial evaluation. Normal results make myocarditis/pericarditis less likely. [1]

43. When Biopsy Should Be Considered

Endomyocardial biopsy should generally be reserved for cases in which it can materially change diagnosis or treatment.

Particularly important indications include:

severe LV dysfunction;
cardiogenic shock;
sustained ventricular arrhythmia;
suspected giant-cell myocarditis;
suspected eosinophilic myocarditis;
rapidly progressive disease;
unexplained fulminant myocarditis;
uncertain diagnosis despite CMR.

The purpose should be diagnostic—not merely to prove or disprove vaccine causality.

44. Research Priorities

The next generation of studies should move beyond passive adverse-event reporting.

44.1 Prospective cardiac cohorts

Patients should undergo:

baseline ECG;
troponin;
CMR;
immune profiling;

followed by standardized longitudinal evaluation.

44.2 Pediatric longitudinal studies

Children should be followed for:

five;
seven;
ten;

years where feasible.

Endpoints should include:

ventricular function;
CMR scar;
arrhythmias;
exercise capacity;
sudden cardiac events;
heart failure.

44.3 Autopsy registry

An international registry should capture:

vaccination chronology;
product;
dose;
age;
sex;
infection status;
complete cardiac pathology;
toxicology;
molecular pathology.

44.4 Spatial molecular pathology

Single-cell and spatial transcriptomics should identify which cells express inflammatory pathways.

44.5 Proteomics

Proteomic analysis should determine whether post-vaccination myocardium contains:

spike antigen;
altered myocardial proteins;
complement components;
platelet proteins;
inflammatory mediators.

44.6 Host genetics

Whole-exome or whole-genome sequencing should be considered in severe pediatric and fatal cases.

45. What Pathologists Should Put in the Report

A pathology report should avoid unsupported statements such as:

“Death caused by COVID-19 vaccination.”

Instead:

Morphological diagnosis:

Acute lymphocytic myocarditis with focal cardiomyocyte necrosis.

Ancillary findings:

Predominantly CD4-positive T-cell infiltrate with associated macrophages. No SARS-CoV-2 RNA identified by validated assay.

Interpretation:

The findings are compatible with acute myocarditis occurring temporally after COVID-19 vaccination. Histopathology alone is not specific for vaccine causation. Correlation with vaccination chronology, SARS-CoV-2 infection status, clinical findings, cardiac imaging, medication exposure and other potential causes is required.

This approach preserves scientific rigor while recognizing a potentially important adverse event.

46. What Physicians Should Tell Patients

The scientifically defensible message is neither absolute reassurance nor alarm.

A patient should be told:

myocarditis after mRNA COVID-19 vaccination is a recognized uncommon adverse event;
it occurs disproportionately in adolescent and young adult males;
it usually develops within days, especially after dose 2;
most patients recover clinically;
ventricular function usually recovers;
some patients retain CMR abnormalities;
persistent LGE does not automatically mean future heart failure;
long-term significance remains uncertain;
recurrent symptoms warrant evaluation.

The same principle applies particularly strongly to children.

47. Conclusions

The pathology of cardiac injury temporally associated with COVID-19 vaccination is real but heterogeneous.

The strongest evidence concerns myocarditis and pericarditis after mRNA vaccination. The epidemiological association is sufficiently robust that CDC recognizes a causal relationship, and FDA has incorporated myocarditis/pericarditis warnings into vaccine labeling. [1,2]

Histopathologically, however, “myocarditis” is not a single lesion.

Documented patterns include:

CD4-predominant lymphocytic inflammation;
lymphohistiocytic myocarditis;
eosinophilic inflammation;
giant-cell myocarditis;
cardiomyocyte necrosis;
myocardial edema;
contraction-band necrosis;
macrophage infiltration;
complement-associated injury;
and, in some cases, microvascular thrombosis.

The pediatric phenotype is particularly important. Most adolescent patients experience clinical and functional recovery, but persistent CMR abnormalities—especially LGE—occur in a substantial proportion. [11,12,15]

The existence of persistent LGE establishes an important scientific question rather than an established long-term disease outcome: does residual myocardial scar after vaccine-associated myocarditis represent an innocuous remnant of resolved inflammation, or does it create a clinically meaningful substrate for future arrhythmia or cardiomyopathy?

That question cannot be answered adequately by VAERS or other passive surveillance systems.

Nor can it be answered by isolated case reports.

It requires prospective longitudinal CMR, rhythm monitoring, functional assessment, molecular pathology and long-term outcome studies.

For other cardiovascular conditions—myocardial infarction, coronary thrombosis, stress cardiomyopathy, hypertension, arrhythmia, aortic disease and systemic thrombosis—the evidence is substantially less definitive and is much more vulnerable to confounding by age, underlying cardiovascular disease, SARS-CoV-2 infection and background event rates.

The proper scientific posture is therefore neither dismissal nor indiscriminate attribution.

The emerging evidence supports a genuine, uncommon vaccine-associated inflammatory cardiac syndrome. It also demonstrates that the myocardium can display several distinct pathological responses following vaccination, ranging from transient edema to inflammatory injury, cardiomyocyte necrosis, fibrosis and, exceptionally, fatal arrhythmogenic cardiac failure.

The central unresolved question is not whether post-vaccination myocardial injury exists.

It does.

The important questions now are why it occurs, why particular young males are disproportionately susceptible, which lesions are reversible, which produce permanent myocardial scar, whether persistent CMR abnormalities predict future arrhythmia, and which immunological, genetic, endothelial and molecular pathways determine susceptibility.

Answering those questions requires the convergence of clinical cardiology, cardiovascular pathology, forensic pathology, immunology, molecular virology, genomics, proteomics, CMR and long-term epidemiology.

References and Footnotes

1. CDC. Clinical Considerations: Myocarditis and Pericarditis after Receipt of COVID-19 Vaccines Among Adolescents and Young Adults. The CDC states that evidence from multiple U.S. and international surveillance systems supports a causal association between mRNA COVID-19 vaccines and myocarditis/pericarditis, with the highest frequency among adolescent and young adult males after the second dose.

2. U.S. Food and Drug Administration. FDA Approves Required Updated Warning in Labeling of mRNA COVID-19 Vaccines Regarding Myocarditis and Pericarditis Following Vaccination. June 25, 2025. The FDA required updated labeling for Comirnaty and Spikevax concerning myocarditis/pericarditis and cardiac-MRI findings.

3. CDC/ACIP. Updated COVID-19 vaccine safety evidence. Surveillance demonstrates substantial age-, sex-, product- and dose-specific differences in myocarditis/pericarditis rates.

4. Fatima M, et al. Development of myocarditis and pericarditis after COVID-19 vaccination in adult population: systematic review. Ann Med Surg. 2022. Symptoms generally developed within days, with approximately three-quarters of reported cases following dose 2.

5. Development of myocarditis and pericarditis after COVID-19 vaccination in children and adolescents: systematic review. The review identified a strong male predominance and frequent occurrence after the second Pfizer-BioNTech dose.

6. Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series. Fifteen patients with suspected vaccine-associated myocarditis demonstrated myocardial inflammation in 14; diagnoses included acute myocarditis, inflammatory cardiomyopathy and giant-cell myocarditis. Spike protein was detected sparsely in cardiomyocytes in nine patients.

7. Myocarditis following mRNA COVID-19 vaccination: call for endomyocardial biopsy. Among 24 biopsy specimens, acute lymphocytic myocarditis, chronic lymphocytic myocarditis, healed myocarditis, cardiac sarcoidosis and other myocardial injuries were identified.

8. Schwab C, Domke LM, Hartmann L, et al. Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2 vaccination. Clin Res Cardiol. 2023;112:431–440. Twenty-five unexpected deaths within 20 days of vaccination were investigated; four mRNA-vaccinated individuals had acute myocarditis/myopericarditis without another sufficient cause of death.

9. Gill JR, Tashjian R, Duncanson E. Autopsy Histopathologic Cardiac Findings in 2 Adolescents Following the Second COVID-19 Vaccine Dose. Arch Pathol Lab Med. 2022;146:925–929. The myocardial lesions resembled catecholamine-mediated toxic/stress cardiomyopathy rather than conventional myocarditis.

10. Clinical and Histopathological Characteristics of Patients With Myocarditis After mRNA COVID-19 Vaccination. A multicenter Japanese investigation found varying histological phenotypes; cardiomyocyte injury was strongly associated with fulminant clinical disease and mechanical circulatory support.

11. Follow-up cardiac magnetic resonance in children with vaccine-associated myocarditis. Ten adolescents underwent follow-up CMR at a median of 92 days; LGE persisted in 80%, although it decreased in extent in every patient.

12. Post-acute midterm follow-up cardiac MRI findings and clinical outcomes in patients with COVID-19 vaccine-associated myocarditis: systematic review and meta-analysis. Among 126 patients, LGE persisted in approximately 76% at intermediate follow-up, although clinical symptoms generally resolved and LVEF improved.

13. Cardiovascular Sequelae of the COVID-19 Vaccines. A review of 166 publications identified myocarditis, pericarditis, acute coronary syndrome, stress cardiomyopathy, hypertension, tachycardia, MINOCA, cardiac arrest, VITT, MI, CVT, DVT and PE among reported cardiovascular events.

14. COVID-19 Vaccination-Associated Myocarditis in Adolescents. Multicenter U.S. study of 63 patients younger than 21 years; 92% were male, most followed dose 2, and 88% met CMR Lake Louise criteria.

15. Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis. Prospective multicenter registry of 56 pediatric patients; no severe heart failure, transplantation or death occurred, although residual symptoms and diagnostic abnormalities persisted in a subset.

16. Coronavirus Disease 2019 Coronary Vascular Thrombosis: Correlation with Neutrophil but Not Endothelial Activation. Cardiac autopsy material from COVID-19 patients demonstrated extensive vascular thrombosis without the histological pattern of conventional lymphocytic myocarditis.

17. Cardiovascular magnetic resonance imaging and clinical follow-up in patients with clinically suspected myocarditis after COVID-19 vaccination. Myocardial edema resolved and LVEF normalized in a subgroup, although minimal LGE persisted in approximately 48%.

18. Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea. Autopsy demonstrated isolated atrial myocarditis, C4d-positive cardiomyocyte injury and extensive contraction-band necrosis without myocardial microthrombosis or infection.

19. An autopsy case of fulminant myocarditis after SARS-CoV-2 vaccine inoculation. Severe myocarditis with extensive myocytolysis and T-lymphocyte/macrophage infiltration was identified; broad molecular testing did not detect cardiotropic viruses.

20. Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis. Systematic review of 28 reported autopsy cases; the authors concluded that the clinical-pathological evidence supported causal association in those selected cases. This conclusion remains subject to the limitations inherent in published case-series and autopsy literature.

21. Fatal arrhythmia in a young man after COVID-19 vaccination: an autopsy report. Autopsy demonstrated scattered inflammatory foci and cardiomyocyte necrosis after a fatal arrhythmic event.

22. An autopsy case report of aortic dissection complicated with histiolymphocytic pericarditis and aortic inflammation after mRNA COVID-19 vaccination. The case demonstrated pericardial and aortic-adventitial inflammation in association with aortic dissection. Causality cannot be established from a single case.

23. Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. Cardiac autopsies in COVID-19 demonstrated extensive microthrombosis and fibrin/complement deposition, emphasizing the importance of distinguishing infection-associated thrombotic myocardial injury from vaccine-associated myocarditis.

24. Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of BNT162b2. Autopsy identified CD61/CD42b-positive microthrombi in the heart and multiple other organs with a distribution interpreted as TMA-like. This remains a single-case observation.

25. Autopsy findings of COVID-19 in children: systematic review and meta-analysis. Pediatric COVID-19 autopsies demonstrated myocardial edema, band necrosis, fibrin microthrombi, interstitial/perivascular inflammation and pancarditis, illustrating the substantial pathological overlap between infection-associated and vaccine-associated inflammatory cardiac disease.

Important methodological footnote

The literature contains three fundamentally different types of evidence that should not be conflated:

A. Epidemiological evidence establishes whether an event occurs more frequently than expected after vaccination.

B. Clinical/imaging evidence establishes myocardial injury in living patients.

C. Histopathological evidence establishes the anatomical lesion.

None alone necessarily proves individual causation.

The strongest causal inference arises when all three converge with:

close temporal relationship;
characteristic clinical phenotype;
compatible pathology;
exclusion of SARS-CoV-2 infection;
exclusion of alternative viral, toxic, autoimmune and ischemic causes;
reproducible biological mechanism;
and consistency with population-level epidemiology.

That hierarchy is particularly important for publication in a pathology journal because a cardiac event occurring after vaccination is not synonymous with a cardiac event caused by vaccination.

At the same time, the pathological literature now makes it scientifically untenable to characterize all post-vaccination myocarditis as merely coincidental: CDC and FDA recognize the association, and multiple independent biopsy, CMR and autopsy studies demonstrate objective myocardial injury in affected patients.